Trials / Completed
CompletedNCT04560738
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
A Phase 1, Single Center, Open Label Study to Evaluate the Metabolism and Excretion of [14C] CC 92480 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Celgene · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-92480.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-CC-92480 | Oral |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2021-05-13
- Completion
- 2021-05-13
- First posted
- 2020-09-23
- Last updated
- 2021-11-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04560738. Inclusion in this directory is not an endorsement.